FASgen

FASgen is a biotechnology company dedicated to the discovery and development of novel therapeutic agents that target Fatty Acid Synthase (FASN). Founded by a team of researchers from Johns Hopkins University, the company leverages the discovery that FASN is highly expressed in various cancers and plays a critical role in tumor cell survival and metabolic regulation. FASgen's pipeline includes small molecule inhibitors designed to treat a range of conditions, including solid tumors, obesity, and multi-drug resistant tuberculosis. While the company was a pioneer in the field of fatty acid metabolism in disease, its primary assets have largely remained in the pre-clinical or early clinical stages.